Episcleritis and scleritis: clinical features and treatment results

• Published in: American journal of ophthalmology 2000-10, Vol.130 (4), p.469-476
• Main Authors: Jabs, Douglas A., Mudun, Abdulbaki, Dunn, J.P., Marsh, Marta J.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents - therapeutic use; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Biological and medical sciences; Child; Cyclophosphamide - therapeutic use; Diseases of cornea, anterior segment and sclera; Female; Glucocorticoids - therapeutic use; Humans; Immunosuppressive Agents - therapeutic use; Indomethacin - therapeutic use; Male; Medical sciences; Middle Aged; Ophthalmology; Prednisone - therapeutic use; Retrospective Studies; Scleritis - diagnosis; Scleritis - drug therapy; Treatment Outcome; Visual Acuity
• ISSN: 0002-9394; 1879-1891
• DOI: 10.1016/S0002-9394(00)00710-8

PURPOSE: To evaluate the clinical experience with episcleritis and scleritis at a tertiary care eye center. METHODS: Retrospective chart review. RESULTS: One hundred thirty-four patients with scleral inflammation were seen over a 12-year period. Thirty-seven patients had episcleritis, and 97 patients had scleritis. Ocular complications occurred in only 13.5% of patients with episcleritis but in 58.8% of patients with scleritis ( P < .0001). No patient with episcleritis had a decrease in visual acuity, whereas 15.9% of patients with scleritis did. Only 16.7% of patients with episcleritis required more than topical corticosteroids for treatment, and these patients required oral nonsteroidal anti-inflammatory drugs. Conversely, 30.4% of patients with scleritis required nonsteroidal anti-inflammatory drugs, 31.9% oral prednisone, and 26.1% systemic immunosuppressive drugs ( P < .0001). Necrotizing scleritis and posterior scleritis more often were associated with ocular complications, occurring in 91.7% and 85.7%, respectively, than were diffuse anterior scleritis and nodular anterior scleritis ( P = .020). Patients with necrotizing scleritis and posterior scleritis were more likely to be treated with oral corticosteroids or immunosuppressive drugs (90% and 100%, respectively) than were patients with diffuse anterior scleritis and nodular anterior scleritis (56.4% and 21.4%, respectively, P = .002). CONCLUSIONS: Scleritis is a severe ocular inflammation, often associated with ocular complications, and nearly always treated with systemic medications. Nearly 60% of these patients will need oral corticosteroids or immunosuppressive drugs to control the disease.